VenoStent Announces $2.3M in Seed Funding to Transform Vascular Access Surgery for Hemodialysis Patients
VenoStent Announces $2.3M in Seed Funding to Transform Vascular Access Surgery for Hemodialysis Patients
02/23/21, 2:05 PM
Location
nashvilleMoney raised
$2 million
Round Type
seed
VenoStent, a Houston-based advanced materials company, today announced $2.3M in seed funding. The company leverages its unique polymer engineering technology to develop bioresorbable slip-on polymer wraps, called SelfWrap. The product is aimed to eliminate vascular surgery failures, at first targeting vascular access surgery required to initiate hemodialysis treatment for end-stage renal disease (ESRD) patients.
Company Info
Location
nashville, arkansas, united states
Additional Info
VenoStent is an advanced materials company with patented core technology in polymer engineering. Its first product, SelfWrap, is a slip-on, bioresorbable wrap aimed to eliminate vascular access surgery failure rate of 55-65% in hemodialysis patients. The extra costs to the Centers for Medicare and Medicaid Services (CMS) created by these failures amounts to over $2 billion per year.